Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-01-08 @ 12:08 PM
Study NCT ID:
NCT00623233
Status:
COMPLETED
Last Update Posted:
2012-01-09
First Post:
2008-02-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-03
Start Date Type:
None
Primary Completion Date:
2011-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-01
Completion Date Type:
ACTUAL
First Submit Date:
2008-02-13
First Submit QC Date:
None
Study First Post Date:
2008-02-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-12-02
Results First Submit QC Date:
None
Results First Post Date:
2012-01-09
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-12-02
Last Update Post Date:
2012-01-09
Last Update Post Date Type:
ESTIMATED